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Introduction. The aim of this retrospective, unicentric study over 5 years is to describe the epidemiologic, pathologic, clinic and
therapeutic aspects of children treated for Hodgkin lymphoma in our paediatric oncology unit. Patients and Methods.F r o m
January 2005 to December 2009, all children under 18 years of age, with Hodgkin lymphoma were included in this study. The
treatment protocol was the GFAOP (Groupe Franco—Africain d’Oncologie P´ ediatrique) Hodgkin lymphoma treatment protocol.
Results. During the study period, 217 cancer cases were diagnosed in our centre. Of these cases, 7 were Hodgkin Lymphoma (LH)
(0.04%). The mean age was 11.7 years. The sex-ratio was 6/1. 4% (5/7) of patients were stage IIB and 28.6% (2/7) stage IIIB of
Ann-Arbor classiﬁcation. There were 3 cases (42.8%) of sclero-nodular subtype, 2 cases (28.6%) of lymphocyte-rich classical HL
subtype, 1 case (14.3%) of mixed cellularity and 1 case (14.3%) of lymphocyte depleted subtype. With a median followup of 37
months, 5 patients (71.4%) are alive, and 2 patients (28.6%) died. Conclusion. Broader multicentric studies are needed for more
accurate data on this malignancy.
1.Introduction
Hodgkin’s disease, today known as Hodgkin lymphoma, is
amalignanttumorofthelymphoidtissue which accountsfor
less than 1% of all new cases of cancer throughout the world
[1, 2].
About 20000 new cases of Hodgkin lymphoma are
diagnosed each year in North America and Europe [3].
While the annual incidence of non-Hodgkin lymphoma
is 2.2 to 3.8 cases per 100000 inhabitants in Central Africa,
that of Hodgkin lymphoma is unknown in most parts of
Africa [4].
While publications on the disease from Western coun-
tries and the rest of the world are numerous in medical
literature, very few data are available in Africa [5].
The aim of this retrospective study over ﬁve years
(median followup of 37 months) is to describe the epi-
demiological, pathological, clinical, and therapeutic aspects
of all the cases of Hodgkin lymphoma treated in our pedi-
atric oncology unit of Gabriel Tour´ eT e a c h i n gH o s p i t a li n
Bamako.
2.Patientsand Methods
Mali is one of the most underprivileged countries in the
world [6]. Socioeconomic problems limit access to health
care for most citizens and consequently, the treated cases do
not reﬂect the actual epidemiology of the disease.
Our pediatric oncology unit is the only structure in the
country specialized in the treatment of childhood cancer.
Any patient with histologically proven Hodgkin lymphoma,
not previously treated by chemotherapy, was included in this
retrospective unicentric study, from 1 January 2005 to 31
December 2009. After a suspected case of Hodgkin lym-
phoma, a lymph node biopsy was performed by a pediatric
surgeon, and the biopsy specimen was sent to Germany2 Advances in Hematology
(Dr. Klaus Dunke, University of M¨ unster) for pathology and
immunohistochemistry.
The diagnosis criteria for Hodgkin Lymphoma were
those of WHO classiﬁcation [7, 8].
Furthermore, all the patients had a full clinical exam-
ination, including otorhinolaryngologic examination and
a number of additional tests such as blood count, sedimen-
tation rate, renal and liver function tests, chest radiography,
and abdominopelvic ultrasound. In view of our technical
diﬃculties, some additional tests could not be done: EBV
serology and CT scan nuclear medicine. Parental consent for
treatment was obtained from parents or guardian of each
child as part of treatment policy.
Bone marrow biopsy has been performed in the two-
stage III cases. Since our country does not have radiation
therapy, our patients were treated exclusively by chemother-
apy. The patients were treated with the hybrid COPP/ABV
(Cyclophosphamide, Oncovin, Procarbazine, Prednisone,
Adriamycin, Bleomycin, and Vinblastine) protocol used by
the sub-Saharan pilot units of “Groupe Franco-African Pae-
diatric Oncology” (GFAOP).
This chemotherapy was conducted as follows: vincristine
1.5mg/m2 day 1, cyclophosphamide 650mg/m2 day 1, pro-
carbazine 100mg/m2 day 1 to day 7, adriamycine (Doxoru-
bicin)35mg/m2 day8,vinblastine 6mg/m2 day8,bleomycin
10mg/m2 day 8, and prednisone 40mg/m2 day 1 to day 14
(Table 1).
Premedication with 25–50mg of hydrocortisone hemi-
succinate was administered IV slowly before each chemo-
therapy. The intertreatment interval was 28 days.
The Ann Arbor classiﬁcation was used for disease staging
[9]. The absence or presence of fever higher than 38◦Cf o r3
consecutivedays,drenchingnightsweats,orunexplainedloss
of 10% or more of body weight in the 6 months preceding
admission are to be denoted by the suﬃxl e t t e r sAo rB ,
respectively.
Two treatment groups were deﬁned in our protocol:
favorable group (stages I and IIA, and mediastinothoracic
indexlessthan0.45andlymphadenopathylessthan6cmand
no contiguous involvement) and unfavorable group (stage
IIB, III, IV or large mediastinum with mediastinothoracic
indexgreaterthanorequalto0.45,lymphadenopathygreater
t h a no re q u a lt o6c mo rv i s c e r a lc o n t i g u i t y ) .F o rt h ef a v o r -
able group, if an evaluation after two COPP/ABV courses
showed a complete remission (disappearance of all clinical,
biological, and radiological signs) or good response (dis-
appearance of clinical and biological signs and reduction
by at least 75% of all maximum diameter products of
all measurable lesions), treatment was stopped after two
additional courses. For the unfavorable group, in case of
complete remission or good response after two courses,
the treatment was stopped after four additional courses.
On the other hand, for cases that do not respond well
(no change or progress) after the ﬁrst assessment to two
courses, a second evaluation was made after two other
courses, a good response after the four therapies led to four
additional courses, and then the treatment was stopped.
Progress of the disease entailed stoppage of the protocol and
a palliative treatment (Figure 1) .T h ed a t aw e r ea n a l y z e do n
SPSS software, version 12.
3.Results
During the study period, a total of 217 cases of childhood
cancer were diagnosed and treated. Of these cases, 7 were
Hodgkin lymphoma, which gives a hospital prevalence of
0.04%. Hodgkin lymphoma was the 7th most common
cancer in our unit after Burkitt’s lymphoma, retinoblastoma,
nephroblastoma, acute leukemia, and malignant germ cell
tumors. 6 out of 7 patients were from the city of Bamako.
The mean age was 11.71 years, ranging from 6 to 15 years
(Table 2). The sex ratio was 6 in favor of boys: 86% against
14%. 57.1% (4/7) of the fathers were farmers, 14.3% (1/7)
weretraders,and71.4%(2/7)werecivilservants.85.7%(6/7)
ofthemotherswerehousewivesandstreetvendors.5patients
had a family of more than 7 members.
85.7% of the parents were of a disadvantaged socio-
economic status. The mean time from the development of
symptoms to diagnosis was 8 months. No diagnosis was
made in less than 3 months. 2 cases were diagnosed after one
year of evolution. At least one B sign was present in all the
cases. Cervical lymphadenopathies were the signs found in
71.4% of the cases.
71.4% (5/7) of the cases were stage IIB of Ann-Arbor
classiﬁcation and 28.6% (2/7) were stage IIIB (Table 3). All
the patients belonged to the unfavorable group.
4 out of 7 patients had lymph nodes whose size was
between 2cm and 4cm, 2 patients had lymph nodes of 5cm
to 6cm, and only one patient had lymph nodes of more than
7cm. Fever was present in 3 out of 7 (42.8%). In two cases,
there were night sweats. The three B signs (weight loss, fever,
and night sweats) were present in two patients.
In 6 of 7 cases (85.7%), the erythrocyte sedimentation
rate was high (more than 10mm at ﬁrst hour); it was
normal in one case. Histologically, the following were noted:
42.8% of scleronodular subtype, 28.6% of lymphocyte-rich
subtype, 14.3% of mixed cellularity subtype, and 14.3% of
lymphocyte-depleted subtype.
3 patients had a hemoglobin level below 12g/dl and 4
had a hemoglobin level between 12 and 14g/dl. 3 patients
(42.9%) had a widened mediastinum at diagnosis (>0.45 the
thoracic diameter).
34 courses of chemotherapy were evaluated: two deaths
from drug toxicity were recorded.
With a median followup of 37 months, 5 of 7 patients
(71.4%) remain in complete remission, whereas 2 of 7
(28.6%) have died of complications of treatment.
4.Discussion
In 60 months, we recorded only 7 patients with Hodgkin
lymphoma. The small sample size is due partly to the rarity
of this disease and to the fact that people in other regions
of Mali do not have access to our single national centre for
cancer in children. People in the hinterland had diﬃculties
accessing thecentreduetopovertywhich aﬀectsthemajority
of Mali’s population and the long distance.Advances in Hematology 3
E
E
Favorable disease
Stop COPP/ABV∗2
E
E
Stop
End of protocol
Unfavorable disease
COPP/ABV∗4
Stop
End of protocol
Stop
GR
GR
BR
Prog
GR
BR
Prog
BR
GR
BR
COPP/ABV∗2
COPP/ABV∗4
COPP/ABV∗2 COPP/ABV∗2
Stop
Figure 1: General treatment diagram. GR: good responder, BR: bad responder, E: evaluation, and Prog: progressive disease.
Table 1: GFAOP Hodgkin Lymphoma treatment Protocol.
COPP/ABV D1-D2-D3-D4-D5-D6-D7-D8···D14
Vincristine···1.5mg/m2
￿
Cyclophosphamide···650mg/m2
￿
Procarbazine···100mg/m2
Doxorubicin···35mg/m2  
Vinblastine···6mg/m 2
Bleomycine···10mg/m2
Prednisone···40mg/m2
D: day.
Although the diagnosis of cancer is generally diﬃcult
in most African countries due to insuﬃcient resources and
diagnostic facilities, itis recognized that Hodgkin lymphoma
is rare in most of these countries, such as Nigeria where over
5 years Tanko et al. identiﬁed only three cases of Hodgkin’s
disease outof87(3.4%)pediatric solidcancers[5].Thesame
observation was made by Stiller, who admitted that Hodgkin
lymphoma was relatively rare in many developing countries
and Japan [10]. Makata et al. in Kenya also found that
Hodgkin lymphoma accounted for only 4.1% of all pediatric
solid cancers recorded in ten years from 1979 to 1994 [11].
Olweny et al. in Uganda treated in 10 years (1967–1977)
only48 patientsunder16years oldwith Hodgkinlymphoma
[12]. In Dakar (Senegal), Ka et al. recorded only 7 cases
of pediatric Hodgkin lymphoma in 11 years from January
1990 to December 2000 [13]. These results show that despite
diﬃculties of diagnosis in Africa, Hodgkin lymphoma in
children remains rare.
Hodgkin lymphoma ranked seventh among cancers in
children in our unit. Tanko in his series found that Hodgkin
lymphoma was ﬁfth among pediatric cancers [5].
Theaverageageinourserieswas11.7yearswithextremes
of 6 and 15 years. As in other developing countries, the 6–
1 4y e a r sa g eg r o u pi sm o s ta ﬀected by Hodgkin lymphoma
[13, 14].
Our average age is higher than that of Stefan et al. in
South Africa, who found an averageage of 8 years 11 months
[15].4 Advances in Hematology
Table 2: Characteristics of patients.
Characteristics Number Percentage
Sex
Male 6 85.7
Female 1 14.3
Age
Median 12 years
Histology
Scleronodular 3 42.8
Lymphocyte-rich 2 28.6
Mixte cellularity 1 14.3
Lymphocyte depleted 1 14.3
Stage
IIB 5 71.4
IIIB 2 28
Fever 3 42.8
Weight loss 2 28.6
Night Sweats 2 28.6
Weight loss + fever 2 28.6
Weight loss + fever + night sweats 2 28.6
High sedimentation Rate 6 85.7
Diagnosis delay
<3m o n t h s 0 0
4–12 months 5 71.4
>12 months 2 28.6
Hemoglobin < 12g/dl 3 42.8
12 ≤ Hemoglobin ≤ 14 4 57.2
In a multicentric study conducted in USA by Donaldson
etal.on110childrenwith Hodgkinlymphoma stage Iand II,
theaverageagewas13years[16].Inanotherstudyconducted
by Friedmann et al. in USA, 56 children were suﬀering from
Hodgkin lymphoma (unfavorable group); the average age
was 15 years [17].
It appears that Hodgkin lymphoma is relatively rare in
Blacksas shown in the same study by Donaldson, where only
11% of the patients were African-Americans as against 82%
of Whites [16].
It also appears that Hodgkin’s disease is rare in devel-
oping countries where the peak incidence occurs before
adolescence, as was the case in our study [9].
In light of all these observations, we could say that
the peak incidence of Hodgkin lymphoma is earlier in low
income countries compared to that observedin high-income
countries.
In our series, male predominance is signiﬁcant with a sex
ratio of 6/1. The high sex ratio could be partly related to
the small size of our sample. However, male predominance
in Hodgkin lymphoma is reported by many authors in
developed and developing countries [15, 17, 18].
Histologically, the scleronodular subtype was dominant
with 42.8% of the cases, followed by the lymphocyte-
rich subtype (28.6%). The mixed cellularity subtype and
lymphocyte depleted subtype had the same frequency of
14.3%. Engel in his South African series of paediatric
Hodgkin lymphoma cases found 89% of the scleronodular
subtype and the rest were mixed cellularity [18].
In India, Laskar, with 251 Hodgkin lymphoma patients,
found 71% of mixed cellularity subtype, 12% scleronodular
subtype, 10% of predominantly lymphocytic subtype, and
7% of subtypes not speciﬁed [19].
In Europe, from a multicenter study involving 47 centers,
Noordijketal.found,regardless ofage,75%ofscleronodular
subtype [20].
Friedmann et al. in USA found, in a population of 56
children with Hodgkin lymphoma, 47 cases of scleronodular
subtype,6casesofmixedcellularity,2casesofpredominantly
lymphocytesubtype,andonecasethatcouldnotbeclassiﬁed
[17].
In Nicaragua, Baez and his team, with 48 patients
admitted in 5 years, recorded 52.1% (25) cases of mixed
cellularity, 31.2% (15) of scleronodular subtype, 10.4% (5)
of lymphocyte-rich subtype, and 6.3% (3) of lymphocyte
depleted subtype [21].
In our study, and consistent with the literature, the scle-
ronodular subtype is the most common [9].
On the other hand, the mixed cellularity subtype is pre-
dominant in India and Latin America.
71.4% of our patients had a B sign compared to Fried-
mann’s study in which only 22 patients out of 56 (39%) had
aBs i g n[ 17].
Donaldson in USA found 5 cases of B sign out of 74
patients in stage II [16].
As regards drug toxicity, we observed two toxic deaths by
febrile neutropenia. These deathsoccurred despite an empir-
icaltriple antibiotictreatment. Diﬃcultiesin obtainingaddi-
tional laboratory examinations to document these infections
and adapt the antibiotic treatment and the unavailability of
bloodcultureorsupportivegrowthfactorscouldbethecause
of these deaths. The COPP/ABV hybrid protocol seemed to
be well tolerated in all our patients. This ABVD combination
was recognized as being of low toxicity. Introduced in the
1970sbyBonadonnaandhisItalianteamintothetherapeutic
arsenal of Hodgkin lymphoma, it is now considered the gold
standard treatment for this disease. In addition, it has less
sterile and less leukemogenic activity [3, 22]
Shimabukuro-Vornhagen and his team in Germany
treated 2,715 patients with Hodgkin aged 16–71 years with
COPP/ABVD (COPP/ABV plus Doxorubicin) for the early
stages and BEACOPP (Bleomycin, Etoposide, Doxorubicin,
Cyclophosphamide, Vincristine, Procarbazine, and Pred-
nisone) for the advanced stages. They recorded only three
toxic deaths [23].
About nonlethal toxicity, we recorded one case of alope-
cia, 2 cases of digestive toxicity (nausea and vomiting), and
o n ec a s eo fn o n f e b r i l en e u t r o p e n i a .T h e s eﬁ n d i n g sw e r ei n
agreement with those described in the literature [24].
With a median followup of 37 months, our overall
survival rate is 71%. This rate is signiﬁcantly higher than
that obtained by the Senegalese who, over a period of 11
years, treated seven patients, with six deaths and one lost
to followup. Our result is comparable to that obtained by
Olweny in Uganda who used virtually the same protocol likeAdvances in Hematology 5
Table 3: Additional patient’s characteristics and treatment results.
Sex Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7
Female Male Male Male Male Male Male
Time to diagnosis 4–12 months 4–12 months 4–12 months 4–12 months 4–12 months >12 months >12 months
A g e 1 0y e a r s 8y e a r s 1 5y e a r s 6y e a r s 1 3y e a r s 1 5y e a r s 1 5y e a r s
S t a g e I II II II II I I I I I I I
Histology LR LR SN SN SN MC LD
T r e a t m e n t 6 C6 C6 C6 C6 C2 C 2 C
Response CR CR CR CR CR D D
Progression-free survival 57 + months 47 + months 30 + months 29 + months 20 + months D D
C: courses, CR: complete remission, D: deceased, LR: lymphocyte-rich, SN: scleronodular, MC: mixte cellularity,LD: lymphocyte-depleted.
us(75% forstages I–IIAand 60% for stagesIIIB and IV), but
our sample is much smaller [12].
The 95%overallsurvival rate obtainedby teamsin devel-
oped countries is not comparable to our poor results [3].
We are not comparable to the 95.7% overall survival rate
oflocalizedstagesobtainedbytheFrenchPediatricOncology
Society [25].
Hodgkin lymphoma remains relatively rare among
African children, but multicentric studies admitting a larger
number of young patients with this condition are needed to
further ﬁne-tune the results.
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